171 related articles for article (PubMed ID: 7497597)
1. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Hüsken BC; de Jong J; Beekman B; Onderwater RC; van der Vijgh WJ; Bast A
Cancer Chemother Pharmacol; 1995; 37(1-2):55-62. PubMed ID: 7497597
[TBL] [Abstract][Full Text] [Related]
2. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
[TBL] [Abstract][Full Text] [Related]
3. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
[TBL] [Abstract][Full Text] [Related]
4. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
5. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G
Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412
[TBL] [Abstract][Full Text] [Related]
8. Structural aspects of antioxidant activity of flavonoids.
van Acker SA; van den Berg DJ; Tromp MN; Griffioen DH; van Bennekom WP; van der Vijgh WJ; Bast A
Free Radic Biol Med; 1996; 20(3):331-42. PubMed ID: 8720903
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
10. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Thomas C; Vile GF; Winterbourn CC
Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
[TBL] [Abstract][Full Text] [Related]
12. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
Vile GF; Winterbourn CC
Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
[TBL] [Abstract][Full Text] [Related]
13. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species.
de Jong J; Schoofs PR; Onderwater RC; van der Vijgh WJ; Pinedo HM; Bast A
Res Commun Chem Pathol Pharmacol; 1990 Jun; 68(3):275-89. PubMed ID: 2166963
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
[TBL] [Abstract][Full Text] [Related]
15. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
[TBL] [Abstract][Full Text] [Related]
16. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity.
Novak RF; Kharasch ED
Invest New Drugs; 1985; 3(2):95-9. PubMed ID: 2991163
[TBL] [Abstract][Full Text] [Related]
18. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
19. Antioxidative and cardioprotective effects of Phyllanthus urinaria L. on doxorubicin-induced cardiotoxicity.
Chularojmontri L; Wattanapitayakul SK; Herunsalee A; Charuchongkolwongse S; Niumsakul S; Srichairat S
Biol Pharm Bull; 2005 Jul; 28(7):1165-71. PubMed ID: 15997091
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species.
Kotamraju S; Konorev EA; Joseph J; Kalyanaraman B
J Biol Chem; 2000 Oct; 275(43):33585-92. PubMed ID: 10899161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
